Benzinga - by Lisa Levin, Benzinga Editor.
The Dow Jones closed higher by over 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Emeren Group
- The Trade: Emeren Group Ltd (NYSE: SOL) Director Shah Capital Management acquired a total of 39,709 shares an average price of $3.11. To acquire these shares, it cost around $123,495.
- What’s Happening: Emeren Group posted better-than-expected second-quarter earnings.
- What Emeren Group Does: Emeren Group Ltd is a leading global solar project developer, owner, and operator with a ~3 GW pipeline of projects and IPP assets across Europe, North America, and Asia.
- The Trade: Research Frontiers Incorporated (NASDAQ: REFR) Director Darryl Daigle acquired a total of 6,950 shares at an average price of $1.39. The insider spent around $9,650.
- What’s Happening: Research Frontiers posted a narrower loss for the second quarter.
- What Research Frontiers Does: Research Frontiers Inc is engaged in the development and marketing of technology and devices to control the flow of light.
- The Trade: BIO-key International, Inc. (NASDAQ: BKYI) CEO Michael W Depasquale acquired a total of 5,100 shares at an average price of $0.51. To acquire these shares, it cost around $2,626.
- What’s Happening: BIO-key Intl posted a narrower-than-expected quarterly loss.
- What BIO-key International Does: BIO-key International Inc is a fingerprint biometric technology company. It develops and markets advanced fingerprint biometric identification and identity verification technologies, as well as related identity management and credentialing hardware and software solutions.
Check This Out: Top 5 Tech And Telecom Stocks You'll Regret Missing This Month
Don’t forget to check out our premarket coverage here
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.